A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| AZD1152, TFA Salt | An Aurora kinase inhibitor, used to treat patients with advanced solid tumors. Group: Biochemicals. Alternative Names: 3-[[7-[3-[Ethyl[2- (phosphonooxy) ethyl]amino]propoxy]-4-quinazolinyl]amino]-N- (3-fluorophenyl) -1H-pyrazole-5-acetamide Trifluoroacetic Acid Salt; Barasertib Trifluoroacetic Acid Salt; AZD-1152 Trifluoroacetic Acid Salt. Grades: Highly Purified. CAS No. 957881-03-7. Pack Sizes: 1mg, 5mg, 10mg. Molecular Formula: C??H??FN?O?P; x(C ?HF?O?), Molecular Weight: 587.54. US Biological Life Sciences. |  Worldwide |
| AZD1208 | AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1204144-28-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-15604. |  |
| AZD-1208 | AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. AZD1208 inhibits the activities of PIM1, PIM2 and PIM3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition. Synonyms: AZD1208; AZD 1208. Grade: 0.98. CAS No. 1204144-28-4. Molecular formula: C21H21N3O2S. Mole weight: 379.478. |  |
| AZD1208 hydrochloride | AZD1208 (hydrochloride) is an orally bioavailable and highly selective PIM kinases inhibitor. CAS No. 1621866-96-3. Molecular formula: C21H22ClN3O2S. Mole weight: 415.94. | |
| AZD-1236 | AZD1236 is a potent and reversible inhibitor of human MMP-9 and MMP-12. Uses: Scientific research. Category: Signaling pathways. CAS No. 459814-89-2. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-101276. | |
| AZD1283 | AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithrombotic ED50 values of 3.0 and 10 μg/kg/min, respectively. The doses that induced a larger than 3-fold increase in bleeding time were 33 and 100 μg/kg/min for 3 and 13, respectively. Thus, the therapeutic index (TI) was ≥10 for both compounds. On the basis of these data, compound 3 was progressed into human clinical trials as candidate drug AZD1283. Synonyms: AZD 1283; AZD-1283. Grade: 0.98. CAS No. 919351-41-0. Molecular formula: C23H26N4O5S. Mole weight: 470.544. | |
| AZD1305 | AZD1305 is a potassium channel and sodium channel antagonist. It can inhibit rapidly the activating delayed-rectifier potassium current, L-type calcium current, and inward sodium current. Phase II clinical trials for Arrhythmias, Atrial fibrillation, Atrial flutter and Left ventricular dysfunction were discontinued. Uses: Arrhythmias; atrial fibrillation; atrial flutter; left ventricular dysfunction. Synonyms: AZD-1305; AZD 1305; AZD1305; UNII-CZO834LXQM; UNII-CZO834LXQM; (2-(7-(2-(4-Cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non-3-yl)ethyl)carbamic acid tert-butyl ester. Grade: 98%. CAS No. 872045-91-5. Molecular formula: C22H31FN4O4. Mole weight: 434.51. | |
| azd1390 | azd1390 Inhibitor. Uses: Scientific use. Product Category: T5175. CAS No. 2089288-03-7. |  |
| AZD1390 | AZD1390 is a first-in-class orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases. Group: Inhibitors. CAS No. 2089288-03-7. Pack Sizes: 2mg. Product ID: S8680. Formula: C27H32FN5O2. Smiles: CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| AZD1390 | AZD1390 is a first-in-class, orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases. It can be used to cross the blood-brain barrier suitable for the treatment of intracranial malignancies. Synonyms: AZD-1390; AZD 1390. Grade: ≥98%. CAS No. 2089288-03-7. Molecular formula: C27H32FN5O2. Mole weight: 477.57. | |
| AZD1390 | AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM in cell[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2089288-03-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109566. | |
| AZD1480 | AZD1480 is a novel ATP-competitive inhibitor of JAK1 and JAK2 with IC50 of 1.3nM and 0.26nM, respectively. Group: Biochemicals. Alternative Names: (S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine. Grades: Highly Purified. Pack Sizes: 1mg, 5mg. US Biological Life Sciences. | Worldwide |
| AZD-1480 | AZD-1480 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50s of 1.3 nM and <0.4?nM, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 935666-88-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-10193. | |
| AZD-1480 | AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. Synonyms: AZD1480; AZD-1480; AZD 1480. Grade: 0.98. CAS No. 935666-88-9. Molecular formula: C14H14ClFN8. Mole weight: 348.77. | |
| AZD1656 | AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 919783-22-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15675. | |
| AZD 1656 | AZD 1656 is a potent and selective glucokinase (GK) activator with the potential for the treatment of type 2 diabetes. Synonyms: (S)-3-(5-(Azetidine-1-carbonyl)pyrazin-2-yloxy)-5-(1-methoxypropan-2-yloxy)-N-(5-methylpyrazin-2-yl)benzamide. Grade: 99%. CAS No. 919783-22-5. Molecular formula: C24H26N6O5. Mole weight: 478.50. | |
| AZD-1678 | AZD-1678 is a potent CCR4 receptor antagonist with a pIC50 of 8.6. Synonyms: 2,3-Dichloro-N-(5-fluoro-3-methoxy-2-pyrazinyl)benzenesulfonamide; Benzenesulfonamide, 2,3-dichloro-N-(5-fluoro-3-methoxy-2-pyrazinyl)-. Grade: ≥95%. CAS No. 942137-41-9. Molecular formula: C11H8Cl2FN3O3S. Mole weight: 352.17. | |
| AZD-1678 | AZD-1678 is a potent CCR4 receptor antagonist, with a pIC50 of 8.6[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 942137-41-9. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-109511. | |
| AZD1979 | This active molecular is a MCHr1 (melanin concentrating hormone receptor 1) antagonist originated by AstraZeneca. AZD1979 has excellent DMPK properties and gave good effects on weight loss in animal model. In Jul 2014, AstraZeneca terminated a phase I trial in Obesity in healthy volunteers in USA after stopping criteria were reached. Uses: Obesity. Synonyms: AZD1979; AZD-1979; AZD 1979. (3-(4-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone. Grade: 98%. CAS No. 1254035-84-1. Molecular formula: C25H26N4O5. Mole weight: 462.51. | |
| AZD1981 | AZD1981, as a potent antagonist in a disease relevant cell system, inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM. Synonyms: AZD1981; AZD 1981; AZD-1981. Grade: 98%. CAS No. 802904-66-1. Molecular formula: C19H17ClN2O3S. Mole weight: 388.866. | |
| AZD-2014 | AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. AZD2014 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Synonyms: AZD2014, AZD-2014, AZD 2014, Vistusertib. Grade: 0.98. CAS No. 1009298-59-2. Molecular formula: C25H30N6O3. Mole weight: 462.554. | |
| AZD 2066 | AZD 2066 is a mGluR5 anatagonist. It displays discriminative effects in rats. It is brain penetrant and orally bioavailable. It is used to prevent and treat pain, psychiatric, neurological and other diseases. Synonyms: AZD 2066; AZD2066; AZD-2066; 4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine. Grade: ≥98% by HPLC. CAS No. 934282-55-0. Molecular formula: C19H16ClN5O2. Mole weight: 381.82. | |
| AZD 2066 hydrate | AZD 2066 hydrate is a selective and orally active antagonist of mGluR5. AZD 2066 hydrate has antinociception effects. Grade: ≥99%. Molecular formula: C19H18ClN5O3. Mole weight: 386.33. | |
| AZD 2098 | AZD 2098 is a potent and selective CCR4 receptor antagonist (pIC50 = 7.8) used for the treatment of allergic rhinitis. CCR4 is a molecule that can drive the immune cells toward the tumor cells. Uses: The treatment of allergic rhinitis and asthma. Synonyms: AZD-2098; AZD 2098; AZD2098; 2,3-dichloro-N-(3-methoxypyrazin-2-yl)benzenesulfonamide. Grade: 99%. CAS No. 566203-88-1. Molecular formula: C11H9Cl2N3O3S. Mole weight: 334.18. | |
| AZD2281 (Olaparib) | Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations. Group: Inhibitors. Alternative Names: Ku-0059436. CAS No. 763113-22-0. Pack Sizes: 10mg. Product ID: S1060. Formula: C24H23FN4O3. Smiles: C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| AZD2389 | AZD2389 is a potent and orally active FAP inhibitor. AZD2389 can be used for the study of metabolic dysfunction-associated steatohepatitis[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2791472-12-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-172317. | |
| AZD2423 | AZD2423 is a potent, selective, orally bioavailable and non-competitive negative allosteric regulator of CCR2 chemokine receptor with an IC50 of 1.2 nM for CCR2 Ca2+ flux. Synonyms: N-(4-Chloro-3-fluorophenyl)-4-{[(2R)-4-(2-methyl-2-propanyl)-2-piperazinyl]carbonyl}-1-piperazinecarboxamide; 1-Piperazinecarboxamide, N-(4-chloro-3-fluorophenyl)-4-[[(2R)-4-(1,1-dimethylethyl)-2-piperazinyl]carbonyl]-; AZD-2423. Grade: ≥98%. CAS No. 1229603-37-5. Molecular formula: C20H29ClFN5O2. Mole weight: 425.93. | |
| AZD2423 | AZD2423 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator. AZD2423 has an IC50 of 1.2 nM for CCR2 Ca2+ flux [1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1229603-37-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-135891. | |
| AZD-2461 | AZD-2461 is a potent PARP inhibitor, with IC50s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1174043-16-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13536. | |
| AZD-2461 | AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted to see how it may work to treat solid tumors. The study will also assess the blood levels and action of AZD2461 in the body over a period of time and will indicate whether the drug has a therapeutic effect on solid tumors. Synonyms: AZD2461; AZD 2461. Grade: 0.98. CAS No. 1174043-16-3. Molecular formula: C22H22FN3O3. Mole weight: 395.434. | |
| AZD2716 | AZD2716 is a potent sPLA2 inhibitor (IC50 = 10, 40, and 400 nM for sPLA2-IIa, -V, and -X, respectively). When incubated with HepG2 cells, AZD2716 effectively inhibited sPLA2 activity (IC50 value of <14 nM) and suppressed production of sPLA2-IIa (IC50 = 176 nM). Synonyms: AZD2716; AZD-2716; AZD 2716. (2R)-3-[3-(5-benzyl-2-carbamoylphenyl)phenyl]-2-methylpropanoic acid. Grade: 99%. CAS No. 1845753-81-2. Molecular formula: C24H23NO3. Mole weight: 373.44. | |
| AZD2858 | AZD2858 is a potent and selective GSK3β inhibitor with Ki value of 4.9 nM. It was shown to promote osteoblast differentiation in human adipose-derived stem cells (hADSC) in vitro. Synonyms: AZD-2858; 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide. Grade: >98%. CAS No. 486424-20-8. Molecular formula: C21H23N7O3S. Mole weight: 453.52. | |
| AZD2858 | AZD2858 is a potent, orally active GSK-3 inhibitor, with IC50s of 0.9 and 5 nM for GSK-3α and GSK-3β, respectively, used in the research of fracture healing. Uses: Scientific research. Category: Signaling pathways. CAS No. 486424-20-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15761. | |
| AZD 2858 hydrochloride | The hydrochloride salt form of AZD 2858. AZD 2858 is a potent and selective Glycogen Synthase Kinase-3β (GSK-3β; Ki = 4.9 nM) inhibitor used for Alzheimer's disease therapy with good BBB permeability in a bovine endothelial cell assay. AZD 2858 selectively inhibits GSK-3β-mediated tau phosphorylation (IC50 = 76 nM) in vitro. In rats, oral AZD2858 treatment caused a dose-dependent increase in trabecular bone mass by GSK-3 mediated inhibition of Wnt canonical signaling, making AZD2858 a possible therapeutic candidate for osteoporosis. Uses: The treatment of alzheimer's disease. Synonyms: AZD 2858 hydrochloride; AZD2858 hydrochloride; AZD-2858 hydrochloride; 3-amino-6-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Grade: 98%. CAS No. 486424-21-9. Molecular formula: C21H23N7O3S.HCl. Mole weight: 489.98. | |
| AZD2906 | AZD2906 is a selective agonist of glucocorticoid receptor (GR) that increases micronucleus immature erythrocytes in rat bone marrow with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively. Synonyms: N-((1R,2S)-1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(6-methoxypyridin-3-yl)propan-2-yl)cyclopropanecarboxamide; Cyclopropanecarboxamide, N-[(1S,2R)-2-[[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy]-2-(6-methoxy-3-pyridinyl)-1-methylethyl]-. Grade: ≥95%. CAS No. 1034148-15-6. Molecular formula: C26H25FN4O3. Mole weight: 460.50. | |
| AZD2906 | AZD2906 is a selective glucocorticoid receptor (GR) agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1034148-15-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-113854. | |
| AZD2932 | AZD2932 is a new quinazoline ether inhibitor and is a high affinity inhibitor of VEFGR-2 and PDGFR. It has a balanced ~1:1 ratio of activity vs both VEGFR-2 and PDGFRβ. It is also active on c-Kit and FLT3 with good selectivity on a panel of kinases. Synonyms: AZD2932; AZD 2932; AZD-2932. Grade: >98%. CAS No. 883986-34-3. Molecular formula: C24H25N5O4. Mole weight: 447.49. | |
| AZD-3147 | AZD-3147 is an extremely potent and selective dual inhibitor of mTORC1 and mTORC2. It exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. It has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate. Uses: Azd-3147 has physicochemical and pharmacokinetic properties suitable for development as a potential clinical candidate. Synonyms: AZD3147; AZD-3147; AZD 3147; (S)-1-(4-(4-(1-(cyclopropylsulfonyl)cyclopropyl)-6-(3-methylmorpholino)pyrimidin-2-yl)phenyl)-3-(2-hydroxyethyl)thiourea. Grade: >98%. CAS No. 1101810-02-9. Molecular formula: C24H31N5O4S2. Mole weight: 517.66. | |
| AZD-3161 | AZD 3161 is a Nav1.7-voltage-gated-sodium-channel-inhibitor originated by AstraZeneca. Phase-I clinical trials in Pain and Neuropathic pain was discontinued. Uses: Neuropathic pain; pain. Synonyms: UNII-403N302X2Y; CHEMBL2069427; 403N302X2Y; 1369501-46-1; AZD-3161; AZD3161; AZD 3161; SCHEMBL873691; N-[(3S)-5-(5-methoxypyrazin-2-yl)-3,4-dihydro-2H-chromen-3-yl]-6-(2,2,2-trifluoroethoxymethyl)pyridine-3-carboxamide. Grade: 98%. CAS No. 1369501-46-1. Molecular formula: C23H21F3N4O4. Mole weight: 474.44. | |
| AZD3229 | AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. It selectively inhibits growth of c-Kit mutant with GI50s of 1971 nM and PDGFR mutant with GI50s of 122 nM). AZD3229 demonstrates excellent cross-species pharmacokinetics, shows strong pharmacodynamic inhibition of target, and is active in several in vivo models of GIST. Synonyms: AZD-3229; AZD 3229; N-{4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide. Grade: ≥98%. CAS No. 2248003-60-1. Molecular formula: C24H26FN7O3. Mole weight: 479.51. | |
| AZD3229 | AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 inhibits c-KIT with an IC50 value of 223.3 nM[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2248003-60-1. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112802. | |
| AZD3229 Tosylate | AZD3229 Tosylate, a potent pan-kit mutant inhibitor, is used for the treatment of gastrointestinal stromal tumors (GISTs). Synonyms: N-(4-{[5-Fluoro-7-(2-methoxyethoxy)-4-quinazolinyl]amino}phenyl)-2-(4-isopropyl-1H-1,2,3-triazol-1-yl)acetamide 4-methylbenzenesulfonate (1:1); 1H-1,2,3-Triazole-1-acetamide, N-[4-[[5-fluoro-7-(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]-4-(1-methylethyl)-, 4-methylbenzenesulfonate (1:1). Grade: ≥98%. CAS No. 2248003-71-4. Molecular formula: C31H34FN7O6S. Mole weight: 651.71. | |
| AZD3264 | AZD3264 is a novel IKK2 inhibitor. Synonyms: AZD 3264; AZD-3264; AZD3264. Grade: 98%. CAS No. 1609281-86-8. Molecular formula: C21H23N5O4S. Mole weight: 441.5. | |
| AZD3293 | AZD3293, a spiro compound, has been found to be a β-secretase inhibitor that has good blood-brain barrier penetration and could probably be significant in studies of Alzheimer's disease. It was just planed a Phase III trial in several areas. IC50: 0.2 nM. Synonyms: AZD-3293; AZD 3293; AZD3293; LY3314814; GTPL7789; LY 3314814; GTPL 7789; LY-3314814; GTPL-7789; SCHEMBL9948271; (1r,4r)-4-methoxy-5''-methyl-6'-(5-(prop-1-yn-1-yl)pyridin-3-yl)-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine. Grade: 98%. CAS No. 1628076-74-3. Molecular formula: C26H28N4O. Mole weight: 412.53. | |
| AZD-3409 | AZD-3409 is a potent prenyl transferase inhibitor. AZD-3409 showed higher potency than lonafarnib. AZD3409 inhibits farnesylation to a higher extent than geranylgeranylation. AZD3409 might be active in gefitinib-resistant breast carcinoma. Synonyms: AZD-3409; AZD 3409; AZD3409. Grade: 98%. CAS No. 345915-10-8. Molecular formula: C34H41FN4O4S2. Mole weight: 652.844. | |
| AZD3463 | AZD3463. Group: Biochemicals. Alternative Names: N-(4-(4-Aminopiperidin-1-yl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine. Grades: Highly Purified. Pack Sizes: 1mg. Molecular Formula: C24H25ClN6O, Molecular Weight: 448.95. US Biological Life Sciences. | Worldwide |
| AZD-3463 | AZD-3463 (ALK/IGF1R inhibitor) is an orally active ALK/IGF1R inhibitor, with a Ki of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells[1][2][3]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ALK/IGF1R inhibitor. CAS No. 1356962-20-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15609. | |
| AZD-3463 | AZD-3463 is a potent ALK/IGF1R inhibitor with potential anticancer activity. Synonyms: AZD 3463; AZD3463. Grade: 0.98. CAS No. 1356962-20-3. Molecular formula: C24H25ClN6O. Mole weight: 448.95. | |
| AZD3514 | AZD3514 is an orally activie and selective androgen receptor (AR) inhibitor. AZD3514 androgen-dependently and -independently inhibits AR signal. AZD351 down-regulates nuclear AR levels in human LNCaP prostate cancer cells in the absence of androgen with an pIC50 value of 5.75. AZD3514 can be used for the research of prostate cancer[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1240299-33-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16079. | |
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1, 2, 4]triazolo[4, 3-b]pyridazine (1) addressed hERG and physical property issues, and led to clinical candidate 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Group: Biochemicals. Alternative Names: 1- (4- (2- (4- (1- (3- (trifluoromethyl) -7, 8-dihydro-[1, 2, 4]triazolo[4, 3-b]pyridazin-6-yl) piperidin-4-yl) phenoxy) ethyl) piperazin-1-yl) ethanone; 6- (4-{4- [2- (4-acetylpiperazin-1-yl) ethoxy] phenyl}piperidin-1-yl) -3- (trifluoromethyl) -7, 8-dihydro [1, 2, 4] triazolo [4, 3-b] pyridazine. Grades: Highly Purified. CAS No. 1240299-33-5. Pack Sizes: 10mg, 25mg. Molecular Formula: C25H32F3N7O2, Molecular Weight: 519.56. US Biological Life Sciences. | Worldwide |
| AZD-3514 | AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity. AZD3514 is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer. Synonyms: AZD3514; AZD 3514; AZD-3514. Grade: 0.98. CAS No. 1240299-33-5. Molecular formula: C25H32F3N7O2. Mole weight: 519.56. | |
| AZD3759 | AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. Synonyms: AZD3759; AZD-3759; AZD 3759. Grade: 98%. CAS No. 1626387-80-1. Molecular formula: C22H23ClFN5O3. Mole weight: 459.91. | |
| AZD-3759 hydrochloride | AZD-3759 hydrochloride is an effective, orally active and central nervous system-penetrant EGFR inhibitor. AZD-3759 hydrochloride induces cancer cell apoptosis. Synonyms: AZD3759 hydrochloride; Zorifertinib HCl; Zorifertinib hydrochloride; (R)-4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate hydrochloride. CAS No. 1626387-81-2. Molecular formula: C22H24Cl2FN5O3. Mole weight: 496.36. | |
| AZD3839 | AZD3839, also called CHEMBL2177913, as a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the inhibition of BACE1 impedes the production of Aβ peptide. Synonyms: AZD3839; AZD-3839; AZD 3839. (3S)-3-[2-(difluoromethyl)pyridin-4-yl]-7-fluoro-3-(3-pyrimidin-5-ylphenyl)isoindol-1-amine; CHEMBL2177913; I8ID590133; UNII-I8ID590133; I8ID590133; SCHEMBL1358337; BDBM50398264; (1S)-1-(2-(Difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine; 1227163-84-9; 1H-Isoindol-3-amine, 1-(2-(difluoromethyl)-4-pyridinyl)-4-fluoro-1-(3-(5-pyrimidinyl)phenyl)-, (1S)-. CAS No. 1227163-84-9. Molecular formula: C24H16F3N5. Mole weight: 431.41. | |
| AZD3839 free base | AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1227163-84-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg. Product ID: HY-13438. | |
| AZD3965 | AZD3965 is a potent, selective and orally available monocarboxylate transporter 1 (MCT1) inhibitor with a binding affinity of 1.6 nM, 6-fold selective over MCT2. Phase 1. Group: Inhibitors. CAS No. 1448671-31-5. Pack Sizes: 5mg. Product ID: S7339. Formula: C21H24F3N5O5S. Smiles: CC1=C(C(=NN1)C(F)(F)F)CC2=C(C3=C(S2)N(C(=O)N(C3=O)C)C(C)C)C(=O)N4CC(CO4)(C)O. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| AZD3965 | AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, which is 6-fold selective over MCT2 and does not inhibit MCT4 at 10 μM. Both lactate transport and cell growth are potently inhibited by AZD3965 in lymphoma cell lines that preferentially express MCT1. Lactate transport inhibition in some cell lines also induces a cytotoxic effect. In vitro combination studies show that lactate transport inhibition can enhance the induction of cell death by doxorubicin. Blocking lactate transport in vitro also leads to a rapid inhibition of glucose uptake in the Raji Burkitt's lymphoma cell line. In vivo, AZD3965 is well tolerated and induces a dose- and time-dependent accumulation of lactate in the tumors, suppresses tumor growth and in the Raji model potentiates the effects of Rituxan, doxorubicin and bendamustine. The selective inhibition of lactate transport by the MCT1 inhibitor AZD3965 offers a novel mechanism for targeting the metabolic phenotype in tumors that preferentially express MCT1. Synonyms: (S)-5-(4-hydroxy-4-methylisoxazolidine-2-carbonyl)-1-isopropyl-3-methyl-6-((3-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione; AZD3965; AZD-3965; AZD 3965. Grade: >98%. CAS No. 1448671-31-5. Molecular formula: C21H24F3N5O5S. Mole weight: 515.51. | |
| AZD3965 | AZD3965 Inhibitor. Uses: Scientific use. Product Category: T3210. CAS No. 1448671-31-5. | |
| AZD3965 | AZD3965 is a selective MCT1 inhibitor with a Ki of 1.6 nM, showing 6-fold selectivity over MCT2. Uses: Scientific research. Category: Signaling pathways. CAS No. 1448671-31-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-12750. | |
| AZD3988 | AZD3988 is an orally active diacylglycerol acyl transferase-1 (DGAT-1) inhibitor. AZD3988 has excellent DGAT-1 (human) potency with an IC50 value of 0. 6 nM. AZD3988 can be used for the research of metabolic diseases such as diabetes, obesity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 892489-52-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50861. | |
| AZD 3988 | AZD 3988 is a selective and potent diacylglycerol O-acyltransferase (DGAT) enzyme inhibitor with IC50 value of 0.6 nM. It is selective for DGAT-1 over DGAT-2, cytochrome P450 enzymes and Kv11.1 (hERG). It suppresses adipose tissue TAG synthesis and triacylglyceride (TAG) plasma excursion in rats. It reduces body weight of diet-induced obese rats and may be used as a potential treatment for diabetes and other metabolic diseases. It is orally bioavailable and cell permeable. Synonyms: AZD 3988; AZD-3988; AZD3988; trans-4-[-[[[5-[(3,4-Difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl]amino]phenyl]cyclohexaneacetic acid. Grade: ≥98% by HPLC. CAS No. 892489-52-0. Molecular formula: C23H22F2N4O4. Mole weight: 456.44. | |
| AZD4017 | AZD4017 is a potent, selective, and orally bioavailable 11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor). Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. Synonyms: AZD-4017; AZD 4017; (S)-2-(1-(5-(Cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid. Grade: 96%. CAS No. 1024033-43-9. Molecular formula: C22H33N3O3S. Mole weight: 419.58. | |
| AZD 4017 | AZD 4017 is a potent, selective 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) inhibitor, with an IC50 of 7 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1024033-43-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18053. | |
| AZD4144 | AZD4144 is an orally active NLRP3 inhibitor (EC50: 0.082 μM). AZD4144 effectively inhibits the release of IL-1β when NLRP3 is overactivated, exerting an anti-inflammatory effect. AZD4144 has low inhibitory effect on hERG and low cardiotoxicity. AZD4144 has the potential to study diseases and conditions associated with NLRP3 inflammasome activation[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2890191-41-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-162877. | |
| AZD4320 | AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. Uses: Scientific research. Category: Signaling pathways. CAS No. 1357576-48-7. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112416. | |
| AZD-4320 | AZD-4320 is a new type of BH3 analogue BCL2/BCLxL dual inhibitor. Synonyms: AZD4320. Grade: ≥98% by HPLC. CAS No. 1357576-48-7. Molecular formula: C45H48ClF3N4O7S3. Mole weight: 945.5. | |
| AZD-4547 | AZD4547 is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. AZD4547 binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways, and, so, the inhibition of tumor cell proliferation and tumor cell death. Synonyms: AZD-4547; AZD 4547; AZD4547; N-{3-[2-(3,5-Dimethoxyphenyl)ethyl]-1h-Pyrazol-5-Yl}-4-[(3r,5s)-3,5-Dimethylpiperazin-1-Yl]benzamide. Grade: 98%. CAS No. 1035270-39-3. Molecular formula: C26H33N5O3. Mole weight: 463.582. | |
| AZD4547 (Fexagratinib) | Fexagratinib (AZD4547,ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3. Group: Inhibitors. Alternative Names: ABSK 091. CAS No. 1035270-39-3. Pack Sizes: 5mg. Product ID: S2801. Formula: C26H33N5O3. Smiles: CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| AZD4573 | AZD4573 is a potent inhibitor of CDK9 (IC50 of 1/2 = 16 min) and high selectivity versus other kinases, including other CDK family kinases. Group: Inhibitors. CAS No. 2057509-72-3. Pack Sizes: 2mg. Product ID: S8719. Formula: C22H28ClN5O2. Smiles: CC(=O)NC1CCCC(C1)C(=O)NC2=NC=C(C(=C2)C3=C4CC(CN4N=C3)(C)C)Cl. Storage Conditions: 3 years -20°C powder. | United States; Europe |
| AZD4573 | AZD-4573 (AZD4573) is a potent and selective inhibitor of CDK9, with fast-off binding kinetics and high selectivity versus other kinases. AZD4573 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. Synonyms: AZD-4573; AZD 4573; (1S,3R)-3-acetamido-N-(5-chloro-4-(5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)pyridin-2-yl)cyclohexane-1-carboxamide. Grade: ≥98%. CAS No. 2057509-72-3. Molecular formula: C22H28ClN5O2. Mole weight: 429.94. | |
Our database is helping our users find suppliers everyday.
